Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Massachusetts: - Boston Medical Center — Boston, Massachusetts
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Massachusetts: - Massachusetts General Hospital Cancer Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Massachusetts: - Massachusetts General Hospital Cancer Center — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 3 Recruiting Industry
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade g…
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05566795
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Massachusetts: - Tufts Medical Center — Boston, Massachusetts
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Sponsor: Hoffmann-La Roche
NCT ID: NCT05503264
Sites in Massachusetts: - Brigham and Women's Hospital Department of Neurology — Boston, Massachusetts
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Massachusetts: - Dana Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Sponsor: VBI Vaccines Inc.
NCT ID: NCT03382977
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: Patrick Wen, MD
NCT ID: NCT02977780
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in Massachusetts: - Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Industry
The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recur…
Sponsor: Philogen S.p.A.
NCT ID: NCT06336291
Sites in Massachusetts: - Massachusetts General Hospital (MGH) — Boston, Massachusetts
- Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
- Dana-Farber Cancer Institute (DFCI) — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Massachusetts: - Dana Farber Cancer Institute — Boston, Massachusetts
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pa…
Sponsor: Eikon Therapeutics
NCT ID: NCT06907043
Sites in Massachusetts: - Beth Israel Deaconess Medical Center — Boston, Massachusetts
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Massachusetts: - Dana Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this s…
Sponsor: L. Nicolas Gonzalez Castro, MD, PhD
NCT ID: NCT05463848
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
Glioblastoma (GBM) is an aggressive malignancy of the central nervous system. Older adults with GBM have a unique constellation of medical, psychosocial, and supportive care needs. To address these challenges, prior work has evaluated the …
Sponsor: Brigham and Women's Hospital
NCT ID: NCT06835803
Sites in Massachusetts: - Brigham and Women's Hospital — Boston, Massachusetts
- Dana-Farber Brigham Cancer Center, Milford Hospital — Milford, Massachusetts
- Dana-Farber Brigham Cancer Center, South Shore Hospital — South Weymouth, Massachusetts
Phase 2 Recruiting Academic/Other
This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combin…
Sponsor: Massachusetts General Hospital
NCT ID: NCT02896335
Sites in Massachusetts: - Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT). This research study involves: * NTS-WBRT (normal tissue sparing whole…
Sponsor: Massachusetts General Hospital
NCT ID: NCT05013892
Sites in Massachusetts: - Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or proceed w…
Sponsor: Ayal A. Aizer, MD
NCT ID: NCT07130786
Sites in Massachusetts: - Brigham and Women's Hospital — Boston, Massachusetts
Phase 2 Recruiting Academic/Other
The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation treatment. The inte…
Sponsor: Ayal A. Aizer, MD
NCT ID: NCT07132190
Sites in Massachusetts: - Brigham and Women's Hospital / Dana-Farber Cancer Institute — Boston, Massachusetts